Cargando…

How to Prevent and/or Revert Alzheimer’s Disease Continuum During Preclinical Phases

The development of Alzheimer’s disease (AD) follows three consecutive phases: namely preclinical, prodromal or mild cognitive impairment (MCI), and dementia. In addition, the preclinical phase can be divided into subphases related to the presence of biomarkers that appear at different points before...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ávila-Villanueva, Marina, Dolado, Alberto Marcos, Fernández-Blázquez, Miguel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259072/ https://www.ncbi.nlm.nih.gov/pubmed/37313496 http://dx.doi.org/10.3233/ADR220100

Ejemplares similares

Brain Structural and Functional Changes in Cognitive Impairment Due to Alzheimer’s Disease
por: Ávila-Villanueva, Marina, et al.
Publicado: (2022)

The Role of Chronic Stress as a Trigger for the Alzheimer Disease Continuum
por: Ávila-Villanueva, Marina, et al.
Publicado: (2020)

Subjective Cognitive Decline as a Preclinical Marker for Alzheimer's Disease: The Challenge of Stability Over Time
por: Ávila-Villanueva, Marina, et al.
Publicado: (2017)

Alzheimer’s Disease and Empathic Abilities: The Proposed Role of the Cingulate Cortex
por: Ávila-Villanueva, Marina, et al.
Publicado: (2021)

Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum
por: Milà‐Alomà, Marta, et al.
Publicado: (2020)

Identifying Changepoints in Biomarkers During the Preclinical Phase of Alzheimer’s Disease
por: Younes, Laurent, et al.
Publicado: (2019)

Will It Revert to Pageantry and Burlesque?
Publicado: (1920)

Selecting the most important self-assessed features for predicting conversion to mild cognitive impairment with random forest and permutation-based methods
por: Gómez-Ramírez, Jaime, et al.
Publicado: (2020)

Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma
por: Stefanovic, Milica, et al.
Publicado: (2016)

Revertant Mosaicism in Epidermolysis Bullosa
por: Meyer-Mueller, Cameron, et al.
Publicado: (2022)

Preventing Polio Post-eradication: Revertant Proportion Patterns of OPV Serotypes
por: Altamirano, Jonathan, et al.
Publicado: (2017)

Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal
por: Vermunt, Lisa, et al.
Publicado: (2019)

A "late-but-fitter revertant cell" explains the high frequency of revertant mosaicism in epidermolysis bullosa
por: van den Akker, Peter C., et al.
Publicado: (2018)

Preclinical diagnosis of Alzheimer’s disease: Prevention or prediction?
por: Nitrini, Ricardo
Publicado: (2010)

Alzheimer’s disease: a continuum with visual involvements
por: Elvira-Hurtado, Lorena, et al.
Publicado: (2023)

Cardiomyocyte substructure reverts to an immature phenotype during heart failure
por: Lipsett, D. B., et al.
Publicado: (2019)

Electrophysiological brain signatures for the classification of subjective cognitive decline: towards an individual detection in the preclinical stages of dementia
por: López-Sanz, David, et al.
Publicado: (2019)

Short-term Intervention to Revert Premalignant Lesions as Strategy to Prevent Gastrointestinal Cancers
por: Han, Young-Min, et al.
Publicado: (2013)

MTM1 overexpression prevents and reverts BIN1-related centronuclear myopathy
por: Giraud, Quentin, et al.
Publicado: (2023)

Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice
por: Tasfaout, Hichem, et al.
Publicado: (2017)

Yeast HXK2 gene reverts glucose regulation mutation of penicillin biosynthesis in P. chrysogenum
por: Pérez, Edmundo A., et al.
Publicado: (2014)

On the path to 2025: understanding the Alzheimer’s disease continuum
por: Aisen, Paul S., et al.
Publicado: (2017)

Memory markers in the continuum of the Alzheimer’s clinical syndrome
por: Parra, Mario A., et al.
Publicado: (2022)

The dynamics of plasma biomarkers across the Alzheimer’s continuum
por: Guo, Yu, et al.
Publicado: (2023)

Preclinical Alzheimer’s disease: how to predict who will decline next year?
por: Hanseeuw, Bernard J, et al.
Publicado: (2023)

Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH
por: Tan, Mingjun, et al.
Publicado: (2020)

Oxygen nanobubbles revert hypoxia by methylation programming
por: Bhandari, Pushpak N., et al.
Publicado: (2017)

Reverting Immune Suppression to Enhance Cancer Immunotherapy
por: Guerrouahen, Bella S., et al.
Publicado: (2020)

Revertant somatic mosaicism as a cause of cancer
por: Inaba, Toshiya, et al.
Publicado: (2021)

Maternal Flavonoids Intake Reverts Depression-Like Behaviour in Rat Female Offspring
por: de la Garza, Ana Laura, et al.
Publicado: (2019)

PDEs and Continuum Models of Phase Transitions
por: Rascle, M, et al.
Publicado: (1989)

Lipid Peroxidation Assessment in Preclinical Alzheimer Disease Diagnosis
por: Peña-Bautista, Carmen, et al.
Publicado: (2021)

Longitudinal Clinical and Cognitive Changes Along the Alzheimer Disease Continuum in Down Syndrome
por: Videla, Laura, et al.
Publicado: (2022)

Idarucizumab to revert the anticoagulant effect of dabigatran in traumatic acute subdural haematoma: a case report of first use in Latin America
por: Izaguirre Ávila, Raúl, et al.
Publicado: (2019)

Lack of Ovarian Secretions Reverts the Anabolic Action of Olanzapine in Female Rats
por: Skrede, Silje, et al.
Publicado: (2017)

The Inflammatory Continuum of Traumatic Brain Injury and Alzheimer’s Disease
por: Kokiko-Cochran, Olga N., et al.
Publicado: (2018)

Glial activation and inflammation along the Alzheimer’s disease continuum
por: Nordengen, Kaja, et al.
Publicado: (2019)

Nanoscale Phase Evolution during Continuum Decomposition of Fe-Cr Alloys
por: Li, Yongsheng, et al.
Publicado: (2017)

Small and Innovative Molecules as New Strategy to Revert MDR
por: Zinzi, Laura, et al.
Publicado: (2014)

S-Nitrosoglutathione Reverts Dietary Sucrose-Induced Insulin Resistance
por: Sousa-Lima, Inês, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_piha8v70vm14emighf3vbr138m